Premium
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma
Author(s) -
Lee SungEun,
Min ChangKi,
Yahng SeungAh,
Cho ByungSik,
Eom KiSeong,
Kim YooJin,
Kim HeeJe,
Lee Seok,
Cho SeokGoo,
Kim DongWook,
Lee JongWook,
Min WooSung,
Park ChongWon
Publication year - 2011
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2010.01523.x
Subject(s) - bortezomib , multiple myeloma , osteoclast , osteoblast , alkaline phosphatase , medicine , bone marrow , cancer research , chemistry , enzyme , in vitro , biochemistry , receptor
Osteolytic lesions with activated osteoclast (OC) and suppressed osteoblast (OB) activity are characteristics of myeloma bone lesion. Recently, it has been shown that bortezomib treatment enhances OB function. To evaluate the effect of bortezomib on myeloma bone lesions, we performed bone scans, where increased uptake of the radiopharmaceutical by OBs is associated with re‐building activity. Bortezomib treatment markedly enhanced bone metabolic activity and increased alkaline phosphatase levels, and decreased monoclonal protein levels. These findings suggest that bortezomib has potent anti‐myeloma activity and bone‐protecting effects, with enhanced OB function.